

Program overview

Wednesday, September 24, 2025

11:00 – 12:15 Registration and Lunch

12:15 - 12:30 Welcome by the ECLCB-9 Committee

12:30 - 14:45 SESSION 1: LIVER CELL BIOLOGY

Speakers and moderators: Neil Henderson (UK), Prakash Ramachandran (UK), Ruchi Bansal (Netherlands)

12:30-12:50 Mapping human liver fibrosis using spatial genomics, Neil Henderson (UK)

12:50-13:05 Cystathionine gamma-lyase (CTH) inhibition impairs Liver Sinusoidal Endothelial Cells (LSEC) angiogenic capacity, fenestration and eNOS signaling, Turtushikh Damba (Denmark)

13:05-13:20 A single-cell atlas of the developing murine extrahepatic bile duct, Iris de Jong (Netherlands)

13:20-13:40 A Human Liver Single-cell Atlas Identifies Pro-Inflammatory Scar-associated Macrophages as a Target for Hepatic Fibrosis, Prakash Ramachandran (UK)

13:40-13:55 Lipid nanoparticle mediated delivery of antimir-155 ameliorates liver inflammation and fibrosis in CCl₄-induced liver injury mouse model, Vishal Tuli (Netherlands)

13:55-14:15 Targeting hepatic stellate cells and beyond, Ruchi Bansal (Netherlands)

14:15-14:30 Integrated Metabolic and Gene Expression Remodeling in Hepatic Stellate Cell Activation, Shanthini Kannan (Belgium)

14:30-14:45 Beta-arrestin-2-mediated hepatocyte-HSC interaction promotes HSC activation and fibrogenesis, Robert Schierwagen (Germany)

14:45 – 15:05 Coffee Break, Networking and Posters

15:05 - 17:20 SESSION 2: LIVER MOLECULAR BIOLOGY

Speakers and Moderators: Fabio Marra (Italy), Han Moshage (Netherlands), Zeinab Abdullah (Germany)

15:05-15:25 Molecular signaling in chronic liver disease: From injury to fibrosis, Fabio Marra (Italy)

- 15:25-15:40 STARD1-dependent mitochondrial cholesterol trafficking activates the NLRP3 inflammasome complex in MASH, Sandra Torres Núñez (Spain)
- 15:40-15:55 The endothelial FoxO1 pathway in decompensated liver cirrhosis and acute-on-chronic liver failure, Fabian Schachteli (Germany)

15:55-16:15 Apoptosis and inflammation in liver diseases: Molecular mechanisms and therapeutic implications, Han Moshage (Netherlands)

- 16:15-16:30 Targeting neutrophils recruitment/signaling attenuates biliary disease in a mouse model of Caroli Disease, Anna Palmiotti (USA)
- 16:30-16:45 A Type IV Autotaxin inhibitor, Cambritaxestat (IOA-289), mitigates steatosis and fibrosis in MASLD and MASLD-HCC mouse models by blocking LPAR1 and LPAR6 signaling, Vishal Tuli (Netherlands)

16:45-17:05 Liver Regeneration in Fatty Liver Disease: Molecular mechanisms and therapeutic targets, Zeinab Abdullah (Germany)

17:05-17:20 Detoxification of LPS attenuates its pro-inflammatory and lipogenic effects in *in-vitro* models of MASLD, Eman D. Mohammed (Netherlands)

17:20 – 17:40 Coffee Break, Networking and Posters

17:40 – 18:10 PITCH-YOUR-POSTER SESSION (P1) Pitch 1-10 from selected abstracts (2 minutes each)

- 1. Plasma extracellular vesicles contain protein biomarkers for capturing stages of metabolic dysfunction-associated steatotic liver disease, Yakun Li (Netherlands)
- 2. Genetic correction of Wilson's disease H1069Q mutation in iPSCs using CRISPR/Cas9 technology, Vanessa Sandfort (Germany)
- 3. Constitutive MAS1 G protein-coupled receptor participates in the pathogenesis of liver fibrosis, Sabine Klein (Germany)
- 4. Time-resolved hepatic single cell sequencing during liver fibrosis regression identifies distinct 'regressive' macrophage sub-populations, Katharina Bonitz (Austria)
- 5. Inhibition of ATGL shapes cholangiocyte inflammatory response in vitro, Tanmoy Chakma (Austria)
- 6. Image-Based Deep Profiling of Primary Liver Cells for Disease Phenotyping and Compound Screening Using Machine Learning, Arkajyoti Sarkar (Belgium)
- 7. Clonality analysis of circulating T cells reveals non-epitope-driven clonal expansion in metabolic-associated steatotic liver disease, Xinlei Zhao (Germany)
- 8. GDF15 ameliorates palmitate-induced hepatocyte steatosis by restoring impaired mitochondrial fusion, Jia Li (Netherlands)
- 9. Development of Platelet Derived Growth Factor β Receptor-selective Liposomes, Adam Fajriawan (Netherlands)
- 10. Impaired branched chain amino acid metabolism alters inflammatory and oxidative responses in Kupffer cells in a model of Metabolic dysfunction Associated Steatotic Liver Disease (MASLD), Lizbeth Magnolia Martinez Aguilar (Netherlands)

18:15 – 19:15 Parallel Workshops

Moderators and speakers: Prakash Ramachandran (UK) and Ruchi Bansal (Netherlands)

OMICS enabling understanding, diagnosis and treatment of liver diseases

Moderators and speakers: Ralf Weiskirchen (Germany) and Peter Olinga (Netherlands)

Human-mimic liver disease models

Moderators and speakers: Klaas Poelstra (Netherlands) and Ruchi Bansal (Netherlands)

(Nano) Delivery systems for liver diseases

19:30 NETWORKING DINNER



Thursday, September 25, 2025

08:30 - 09:55 SESSION 3: LIVER MODELS-I

Speakers and moderators: Leo van Grunsven (Belgium) and Krista Rombouts (UK)

08:30-08:50 Studying liver fibrosis using primary mouse liver cells, Leo van Grunsven (Belgium)

- 08:50-09:05 Establishment of a hiPSC-derived liver-on-a-chip model system for personalized drug metabolism studies, Isabel Tamargo (Netherlands)
- 09:05-09:20 Combined stem cell and predictive models reveal flavin cofactors as targets in metabolic liver dysfunction, Julian Weihs (Germany)

09:20-09:40 The biology of gastrointestinal fibrogenesis in 3D: does ECM matter? Krista Rombouts (UK)

09:40-09:55 Ion-specific hydrogel microcarriers with biomimetic niches for bioartificial liver system, Xiang Lin (Finland)

09:55 – 10:15 Coffee Break, Networking and Posters

10:15 - 12:00 SESSION 3: LIVER MODELS-II

Speakers and moderators: Peter Olinga (Netherlands) and Volker Lauschke (Sweden)

10:15-10:35 Precision-cut liver slices: Cutting-edge model for liver disease research, Peter Olinga (Netherlands)

- 10:35-10:50 Activation of the Bile Acid Receptor FXR Reduces Fibrosis in Mouse Kidney Slices, Whereas TGR5 Agonism Induces Nephrotoxicity, Sandra Maria Hansen (Denmark)
- 10:50-11:05 Proteomic Landscape of Liver ECM in Health and Disease and Its Functional Crosstalk with Organoids, Fuchen Dong (Netherlands)

11:05-11:25 Patient-derived 3D liver culture systems for the chemogenomic interrogation of complex physiological processes, Volker Lauschke (Sweden)

- 11:25-11:40 Precursor of chemically expanded hepatocytes (pre-cHep) with 1-million-fold expansion potential and liver repopulation capacity, Keisuke Kaji (UK)
- 11:40-11:55 Metabolic Reprogramming in MASH-Related HCC: The Emerging Role of G6PD as a Biomarker and Target, Jessica Nurcis (Italy)

12:00 - 13:00 Lunch and Posters

13:00 – 13:30 PITCH-YOUR-POSTER SESSION (P2) Pitch 11-20 from selected abstracts (2 minutes each)

- 11. A Comparative Analysis of HepG2 and Fa2N-4 Hepatocyte Models for Steatotic Liver Disease: Implications for Lipid Metabolism and Drug Response, Victoria Palasantzas (Netherlands)
- 12. Metabolic Dysfunction-Associated Steatohepatitis Sensitizes to Acetaminophen Hepatotoxicity, Laura Fàbrega Jiménez (Spain)
- 13. A scalable human primary liver model to study cell-cell interactions, Luuk de Haan (Netherlands)
- 14. The stiffness of liver-derived extracellular matrix hydrogels regulates hepatic stellate cell activation, Qi Zhou (Netherlands)

- 15. Effect of potentially therapeutic bile acids on reactive cholangiocyte phenotype in human biliary organoids, Fabian Heinreichsberger (Austria)
- 16. Advanced drug testing with a 3D in vitro model of human liver fibrosis combining human hepatic cells and biomaterials, Ana Margarida Carvalho (Portugal)
- 17. Fructose and glucose drive the MASLD phenotype and disturb CYP450 regulation in preclinical liver models, Laura Cools (Belgium)
- 18. Human iPSC-derived Liver Fibrosis Model to Study Monocyte Activation and Recruitment, Burak Toprakhisar (Belgium)
- 19. Modulation of the Gut-Liver Axis and Immune Responses in Experimental Liver Fibrosis, Katja Sommer (Austria)
- 20. Somatic CRISPR/Cas9-mediated gene editing in adult mice identifies hepatic KLB as a regulator of bile acid synthesis and hepatic lipid metabolism, Alexandra Aaldijk (Netherlands)
- 21. Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma, Amaya Lopez-Pascual (Spain)

13:30 – 15:15 SESSION 4: INTERORGAN COMMUNICATION

Speakers and moderators: Romina Fiorotto (USA), Bart Staels (France), Gabriela Schiattarella (Germany)

13:30-13:50 Dialogues across the Liver-Gut axis, Romina Fiorotto (USA)

13:50-14:05 Low fiber intake alleviates liver pathology via hepatoprotective UDCA produced by gut microbiota, Wenqiang Shen (Netherlands)

14:05-14:25 Cardio-Hepatic crosstalk in metabolic disease, Bart Staels (France)

14:25-14:40 Lack of CFTR in mice causes liver vascular abnormalities similar to non-cirrhotic portal hypertension, Anna Palmiotti (USA)

14:40-15:00 The Liver-Heart Connection in Heart Failure and Cardiometabolic Diseases, Gabriele Schiattarella (Germany)

15:00-15:15 Understanding sex-dependent hepatic cholesterol handling by studying the lysosomal proteome and interactome, Cristy Verzijl (Netherlands)

15:15 – 15:35 Coffee Break, Networking and Posters

15:35 - 17:50 SESSION 5: CLINICAL SESSION

Speakers and Moderators: Onno Holleboom (Netherlands), Matias Avila (Spain), Joanne Verheij (Netherlands)

15:35-15:55 A clinical perspective on MASLD, Onno Holleboom (Netherlands)

- 15:55-16:10 Circulating Bacteria-Derived Extracellular Vesicles Carrying Virulence Factors Contribute to Hepatic Injury in Autoimmune Hepatitis, Sukriti Baweja (India)
- 16:10-16:25 Lipid–Neutrophil Axis Drives Systemic Inflammation and Organ Injury in Acute-on-Chronic Liver Failure, Pragyan Acharya (India)

16:25-16:45 Epigenetic mechanisms and targets in liver tumors, Matias Avila (Spain)

16:45-17:00 Understanding the impact of the liver microenvironment on regulatory T cells, Maegen Fleming (UK)

17:00-17:15 Targeting SLU7 against cancer, Carla Rojo González (Spain)

17:15-17:35 A clinical perspective on Cholangiocarcinoma, Joanne Verheij (Netherlands)

17:35-17:50 Extracellular Matrix Remodeling in the Progression of Primary Sclerosing Cholangitis to Cholangiocarcinoma: Insights from an Animal Model, Camilla Venturin (USA)

17:50 – 18:30 SESSION 6: INDUSTRY SESSION

18:30 – 19:30 NETWORKING DINNER

19:30 - 22:30 SOCIAL EVENT



Friday, September 26, 2025

08:30 - 10:30 SESSION 7: LIVER DISEASES

Speakers and moderators: Saskia van Mil (Netherlands), Minneke Coenraad (Netherlands)

08:30-08:50 Molecular and cellular implications of FXR alternative splicing in liver physiology and disease, Saskia van Mil (Netherlands)

08:50-09:05 Decreased glycine in hepatic steatosis alters methylation capacity through dysregulation of the methionine cycle, Inbal Mor (Israel)

09:05-09:20 CD4 T helper cells influence the fate decision of facultative liver stem cells, Wei-Yu Lu (UK)

09:20-09:40 Pathophysiology of Acute-on-chronic liver failure, Jonel Trebicka (Germany)

09:40-09:55 Development and characterization of novel rodent ACLF models, Sabine Klein (Germany)

09:55-10:15 Pathophysiology of decompensated cirrhosis, Minneke Coenraad (Netherlands)

10:15-10:30 Plasma-derived extracellular vesicles identify protein signatures (HP, CFHR4, and CNDP1) for decompensated cirrhosis in chronic liver diseases, Lizbeth Magnolia Martinez Aguilar (Netherlands)

10:30 - 10:45 Coffee Break and Posters

10:45 - 11:15 PITCH-YOUR-POSTER SESSION (P3)

- 22. Single-cell analysis uncovers preliminary evidence for a shifted myeloid progenitor landscape in ACLD, Katharina Bonitz (Austria)
- 23. Impact of thermoneutral housing in Acute-On-Chronic Alcohol Related Liver Disease, Monica Barrios López (Spain)
- 24. The Role of Tartaric Acid in the Gut–Liver Axis mediated Decompensation of liver Cirrhosis, Sara Zarei (Germany)
- 25. Generation of an improved murine model for progressive familial intrahepatic cholestasis type 3 (PFIC3), Lixin Ke (Netherlands)
- 26. Role of the NADPH oxidase in the regulation of endoplasmic reticulum (ER) stress in liver tumor cells, Gemma Gonfaus-Ortiz (Spain)
- 27. The role of the NADPH oxidase nox4 in regulating mitophagy and oxidative metabolism in liver tumor cells, Paula Segalés (Spain)
- 28. Metabolic syndrome as a Central Driver of Metastatic Progression in CRC and PDAC, Xiaoyue Chen (Netherlands)
- 29. A Multifunctional Magnetic-Fluorescent Composite Nanoprobe for the Efficient Capture and Real-Time Monitoring of Circulating Tumor Cells in Hepatocellular Carcinoma, Dawei Yang (Netherlands)
- 30. Involvement of the ERG1 potassium channel in cholangiocarcinoma cell biology, Giada Alla Viligiardi (Italy)

11:15 - 13:30 SESSION 8: LIVER-RELATED MALIGNANCIES

Speakers and moderators: Nabil Djouder (Spain), Robert Schwabe (USA), Mathias Heikenwalder (Germany)

11:15-11:35 Metabolic dysfunctions in HCC development, Nabil Djouder (Spain)

11:35-11:50 α-KG–Driven Immune Escape in Hypoxic MASLD-HCC: Amino Acid Metabolism at the Crossroads, Beatrice Foglia (Italy)

11:50-12:10 Uncovering the druggable "master regulators" in HCC and CCA, Robert Schwabe (USA)

- 12:10-12:25 A Novel Approach for the Isolation and Selection of Tumor-Infiltrating B-cells from Resected Tumors of Hepatocellular Carcinoma Patients, Ashmit Mittal (Netherlands)
- 12:25-12:40 The endosomal protein sorting complex retromer plays an essential role in postnatal liver development and liver cancer development, Bart van de Sluis (Netherlands)

12:40-13:00 The role of the liver micro-environment in driving chronic inflammation and cancer: Lessons to learn for therapeutic approaches, Mathias Heikenwalder (Germany)

- 13:00-13:15 Oncostatin M modulates the biology of cholangiocarcinoma cells and the tumor microenvironment, Nunzia Porro (Italy)
- 13:15-13:30 Caspase-8 is a gender-specific inhibitory modulator of cholestasis-induced liver fibrosis and hepatocarcinogenesis in female mice, Christian Penners (Germany)

13:30 – 14:30 Closing Remarks with Presentation (3) and Pitch-Your-Poster (3) awards (with Farewell lunch)

*15:00 – 17:00 Optional Lab Tour (RUG/UMCG) Contact Peter Olinga and Han Moshage (if interested)

SPECIAL THANKS TO ECLCB9 SPONSORS



THIS EVENT IS OFFICIALLY EASL ENDORSED



